< em > Xianling Lianxia < /em > formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer
This study demonstrates that XLLXF can synergistically enhance the efficacy of trastuzumab in targeting HER2-positive BC. The mechanism may involve the modulation of inflammatory factors.PMID:38379418 | DOI:10.3724/abbs.2023281
Source: Acta Biochimica et Biophysica Sinica - Category: Biochemistry Authors: Feifei Li Yuanyuan Wu Youyang Shi Xiaofei Liu Ying Xie Sheng Liu Source Type: research
More News: Biochemistry | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Herceptin | Study